Recruiting
Phase 1

LY5625573

Sponsor:

Eli Lilly and Company

Code:

NCT07867340

Conditions

C-Reactive Protein

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

LY5625573

Midazolam

Placebo

Study Details

Brief summary:

The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them.

Participation in the study will last up to approximately 7 weeks for Part A and 8.5 weeks for Parts B, C, D, and E. For each participant there will be one stay at the clinical research unit (CRU) lasting 5 nights for Part A, 18 nights for Parts B and C, and 17 nights for Parts D and E.

Conditions

C-Reactive Protein

Study ID

NCT07867340

Start date

Sep 29, 2026

Status verified date

Nov, 2026

Completion date

Jan, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • 21 to 65 years of age, inclusive, at the time of signing the informed consent if enrolled in Singapore
  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring
  • Have clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have a hemoglobin level of at least 12.5 grams per deciliter (g/dL) for participants assigned male at birth (AMAB) and at least 11.4 g/dL for participants assigned female at birth (AFAB)
  • Individuals AFAB who are individual not of childbearing potential (INOCBPs) may participate in this trial

Parts A, B, D, and E

  • Have a body mass index (BMI) greater than or equal to (≥)18.5 and less than or equal to (≤) 32.0 kilograms per square meter (kg/m²)
  • Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation 2021, of ≥90 milliliter per minute per 1.73 square meters (mL)/minute/1.73 m² at screening

Part C

  • Have a BMI ≥18.5 and <40.0 kg/m²
  • high-sensitivity C-reactive protein (hsCRP) ≥2 milligrams per liter (mg/L) and ≤15 mg/L at screening and Day -2 (as confirmed by local laboratory).
  • Have an eGFR, using the CKD-EPI creatinine equation 2021, of ≥60 mL/minute/1.73 m² at screening

Part D

  • To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan

Part E

  • To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China

Exclusion Criteria:

  • History of active tuberculosis or presence of active or latent tuberculosis
  • History or evidence of clinically significant opportunistic infection
  • History of serious local infection (for example, cellulitis or abscess) or systemic infection within 90 days prior to screening
  • Have any nonserious but active infections
  • History of more than one episode of herpes zoster infection or history of disseminated herpes zoster infection
  • Have a 12-lead electrocardiogram (ECG) abnormality
  • Clinically significant abnormal laboratory test results at screening, or positive serology test results for hepatitis B surface antigen, hepatitis B core total antibody, hepatitis C virus antibody, or human immunodeficiency virus antigen and antibody, or QuantiFERON®-TB test at screening

Parts A, C, D, and E

  • History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232) or to any excipient in the formulation of LY5625573

Part B

  • History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232), midazolam, or to any excipient in the formulation of LY5625573 or midazolam

Parts B, C, D, and E

  • Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 90 days (at screening and/or Day -1 \[Day 2 for Part B\])
  • Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire (at Day -1\[Day 2 for Part B\]

Study Design

Enrollment

96 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: LY5625573 Part A - Single Dose Healthy

Single dose of LY5625573 administered orally in healthy participants

placebo comparator: Placebo Part A - Single Dose Healthy

Single dose of Placebo administered orally in healthy participants

experimental: LY5625573 + Midazolam Part B - Multiple Dose Healthy

Multiple-ascending dose (MAD) of LY5625573 and midazolam co-administered orally in healthy participants

placebo comparator: Placebo + Midazolam Part B - Multiple Dose Healthy

Multiple doses of Placebo and midazolam co-administered orally in healthy participants

experimental: LY5625573 Part C - Multiple Dose Elevated hsCRP

MAD of LY5625573 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP)

placebo comparator: Placebo Part C - Multiple Dose Elevated hsCRP

Multiple doses of Placebo administered orally in participants with elevated hsCRP

experimental: LY5625573 Part D - Healthy Japanese

MAD of LY5625573 administered orally in healthy Japanese participants

placebo comparator: Placebo Part D - Healthy Japanese

Multiple doses of Placebo administered orally in healthy Japanese participants

experimental: LY5625573 Part E - Healthy Chinese

MAD of LY5625573 administered orally in healthy Chinese participants

placebo comparator: Placebo Part E - Healthy Chinese

Multiple doses of Placebo administered orally in healthy Chinese participants

Interventions

LY5625573

Administered orally as tablet

Midazolam

Administered orally

Placebo

Administered orally as tablet

Primary outcome measure

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to Follow up (Days 12 and 24) ]
  • Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline up to Follow up (Days 12 and 24) ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Fortrea Clinical Research Unit

Recruiting

Dallas, Texas, United States, 75247

Contacts

Principal Investigator:

Gene Voskuhl

More Information

Sponsor

Eli Lilly and Company

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.